07:00 , Jun 14, 2012 |  BC Innovations  |  Tools & Techniques

Vaccines revisited

A team from Oregon Health & Science University and Najít Technologies Inc. has shown that hydrogen peroxide could be a better way to inactivate viral vaccines than conventional methods such as formaldehyde and b-propiolactone.1 Najít,...
07:00 , Aug 4, 2008 |  BioCentury  |  Finance

Acambis chronicles

Acambis chronicles From its five-year high of 393p on Sept. 15, 2003, through July 25 of this year, Acambis (LSE:ACM) has lost 70% of its value. The stock jumped 60% to 185.5p on July 28 after...
07:00 , Sep 18, 2006 |  BC Week In Review  |  Company News

Acambis, Novartis, Centers for Disease Control and Prevention infectious news

ACM said the CDC agreed to purchase an additional 10 million doses of the company's ACAM2000 smallpox vaccine under an existing supply contract. ACM said the new order is worth about $30 million. Under...
07:00 , Sep 18, 2006 |  BioCentury  |  Finance

Ebb & Flow

When Amicus pulled its proposed IPO in July, the genetic disease company was hardly hurting for cash, as it had about $40 million in the bank. Nevertheless, Amicus was clearly ready to listen when existing...
00:25 , Sep 14, 2006 |  BC Extra  |  Company News

Acambis up on ACAM2000, Arilvax news

Acambis (LSE:ACM; ACAM) was up 8p to 144p on Wednesday after announcing a new order for ACAM2000 smallpox vaccine and the settlement of an Arlivax dispute. The U.S. government agreed to purchase an additional 10...
08:00 , Mar 14, 2005 |  BioCentury  |  Finance

Ebb & Flow

TransForm Pharmaceuticals is the third MPM portfolio company in the past few weeks to be taken out by a large pharma company. The exits could help make MPM's limited partners happy, as the firm gears...
02:30 , Mar 9, 2005 |  BC Extra  |  Financial News

Acambis reports earnings

Acambis (LSE:ACM; ACAM) reported fourth quarter and full year 2004 earnings and hinted that in 2005, it may sacrifice profitability in favor of R&D investment. The company also said that a BLA for its Arilvax...
07:00 , Sep 27, 2004 |  BioCentury  |  Strategy

Acambis: Life after the CDC

The trouble with government contracts is that they are binary: you either win them or you don't. When a proposed order worth millions is not taken up, the ramifications for a company can underline the...
07:00 , Sep 27, 2004 |  BioCentury  |  Strategy

Acambis pipeline

Acambis pipeline Product Indication Status ACAM2000 Smallpox Mkt (A) C-VIG Prevent smallpox vaccine side effects Mkt (outside N. America & Israel) Vivotif Typhoid fever Mkt in U.S., Canada Arilvax Yellow fever Submit BLA 1H05 Chimeri...
08:00 , Feb 23, 2004 |  BC Week In Review  |  Clinical News

Arilvax live attenuated yellow fever vaccine regulatory update

ACM temporarily withdrew a BLA for Arilvax vaccine to prevent yellow fever, and expects to resubmit the BLA in the first half of 2005. ACM said that CHIR subsidiary Chiron Vaccines is planning to upgrade...